What You Should Know:
– CorVista Health, a Toronto-based digital health company dedicated to improving cardiovascular disease diagnosis, announced it has closed a $65 million Series C financing, bringing the total funding to nearly $100 million.
– This significant capital provides a runway for ongoing research, development and commercialization efforts for CorVista® System, the company’s non-invasive, point-of-care solution that allows physicians to rapidly test for heart disease.
– The CorVista System is intended to synchronously collect and apply machine learning to a patient’s cardiac and hemodynamic signals to predict the likelihood of cardiovascular diseases without the use of radiation, contrast agents, injections, fasting or exercise.
Want to publish your own articles on DistilINFO Publications?
Send us an email, we will get in touch with you.
– Within minutes of the test, the CorVista Analysis is available in a secure web portal to aid physicians in rapidly diagnosing and treating patients with suspected cardiovascular disease, answering important clinical questions to guide better treatment decisions.
Source: Hit Consultant
